XML 32 R19.htm IDEA: XBRL DOCUMENT
v3.24.1

Financial Instruments | 12 Months Ended
--- | ---
Dec. 31, 2023
Financial Instruments [Abstract] |
FINANCIAL INSTRUMENTS |
NOTE 14:- | FINANCIAL INSTRUMENTS
| a. | Classification of financial assets and financial liabilities:
The financial assets and financial liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9, “Financial Instruments” (“IFRS 9”):
|  | December 31, |
|  | 2023 |  |  | 2022 |
Financial assets: |  |  |  |  |  |
Cash and restricted deposits |  | $ | 2,141 |  |  | $ | 3,634 |
Short term deposits |  |  | 3,000 |  |  |  | - |
Government authorities |  |  | 62 |  |  |  | 45 |
Other receivables |  |  | 203 |  |  |  | 46 |
Investments in financial assets |  |  | 659 |  |  |  | 591 |
Total financial assets at amortized cost |  |  | 6,065 |  |  |  | 4,316 |
Financial liabilities: |  |  |  |  |  |  |  |
Credit from others |  |  | 48 |  |  |  | 102 |
Warrants liability |  |  | 532 |  |  |  | 2,737 |
Lease liability |  |  | 76 |  |  |  | 27 |
Total financial and lease liabilities |  | $ | 656 |  |  | $ | 2,866 |
The tables below are a comparison between the carrying amount and fair value of the Company’s financial instruments as of December 31, 2023, and 2022, which are presented in the financial statements not at fair value (other than those whose amortized cost is a reasonable approximation of fair values):
|  | Carrying amount |  | Fair Value |
|  | December 31, |  |  | December 31, 2023 |
|  | 2023 |  |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Cash and restricted deposits |  | $ | 2,141 |  |  | $ | - |  |  | $ | - |  |  | $ | 2,141 |
Short term deposits |  |  | 3,000 |  |  |  | - |  |  |  | - |  |  |  | 3,000 |
Government authorities |  |  | 62 |  |  |  | - |  |  |  | - |  |  |  | 62 |
Other receivables |  |  | 203 |  |  |  | - |  |  |  | - |  |  |  | 203 |
Investments in financial assets |  |  | 659 |  |  | $ | - |  |  | $ | - |  |  | $ | 659 |
Total financial assets at amortized cost |  | $ | 6,065 |  |  | $ | - |  |  | $ | - |  |  | $ | 6,065 |
Credit from others |  | $ | 48 |  |  | $ | - |  |  | $ | - |  |  | $ | 48 |
Warrants liability |  |  | 532 |  |  |  | - |  |  |  | - |  |  |  | 532 |
Lease liability |  |  | 76 |  |  |  | - |  |  |  | - |  |  |  | 76 |
Total financial and lease liabilities |  | $ | 656 |  |  | $ | - |  |  | $ |  |  |  | $ | 656 |
|  | Carrying amount |  |  | Fair Value |
|  | December 31, |  |  | December 31, 2023 |
|  | 2023 |  |  | Level 1 |  |  | Level 2 |  |  | Level 3 |
Cash and restricted deposits |  | $ | 3,634 |  |  | $ | - |  |  | $ | - |  |  | $ | 3,634 |
Short term deposits |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Government authorities |  |  | 45 |  |  |  | - |  |  |  | - |  |  |  | 45 |
Other receivables |  |  | 46 |  |  |  | - |  |  |  | - |  |  |  | 46 |
Investments in financial assets |  |  | 591 |  |  | $ | - |  |  | $ | - |  |  | $ | 591 |
Total financial assets at amortized cost |  | $ | 4,316 |  |  | $ | - |  |  | $ | - |  |  | $ | 4,316 |
Credit from others |  | $ | 102 |  |  | $ | - |  |  | $ | - |  |  | $ | 102 |
Warrants liability |  |  | 2,737 |  |  |  | - |  |  |  | - |  |  |  | 2,737 |
Lease liability |  |  | 27 |  |  |  | - |  |  |  | - |  |  |  | 27 |
Total financial and lease liabilities |  | $ | 2,866 |  |  | $ | - |  |  | $ |  |  |  | $ | 2,866 |
| b. | Dekel
On March 19, 2020, the Company entered into a securities purchase agreement with Dekel Pharmaceutical Ltd. (“Dekel”) pursuant to which Dekel agreed to invest in the Company through a private placement transaction (the “Private Placement”). At the time of the Private Placement, Dekel was considered as a related party to the Company; however, it is no longer a related party to the Company. In connection with the Private Placement, Dekel received convertible promissory notes (the “Notes”), with an aggregate original principal amount of approximately $350, at an aggregate purchase price of $315 to be paid in several tranches spread across a twelve-month period. In addition, the Company issued a warrant to purchase up to 12,088 ordinary shares of the Company (the “Private Placement Warrant”) and 1,538 ordinary shares. The initial tranche of the Private Placement was for a principal amount of $220 at a purchase price of $5,148. The Notes are unsecured, have a maturity date of March 23, 2021, bear interest at a rate of 12% per annum, and may be converted, at the election of the holder, into ordinary shares at an initial conversion price of $0.35 per ordinary share (the “Fixed Conversion Price”), subject to adjustments. After the six-month anniversary of the issuance of the Notes, the conversion price shall be equal to the lower of the Fixed Conversion Price or 70% of the lowest trading price of the ordinary shares as reported on Nasdaq or any exchange upon which the ordinary shares of the Company are traded at such time, for the 20 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. The Private Placement Warrant is exercisable at any time on or after the actual closing date and on or prior to the close of business on the five-year anniversary of the date of issuance, at an initial exercise price of $0.35 per ordinary share, subject to adjustment. On November 8, 2020, the Notes were terminated and the initial tranche was fully repaid by the Company. General Overview of Valuation Approaches used in the Valuation: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Economic methodology: The warrants’ fair value was calculated using the Black–Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions:
|  | December 31, 2023 |  |  | December 31, 2022 |  |  | March 23, 2020 |
Dividend yield (%) |  |  | 0 |  |  |  | 0 |  |  |  | 0 |
Expected volatility (%) |  |  | 72 |  |  |  | 72 |  |  |  | 122.01 |
Risk-free interest rate (%) |  |  | 3.84 |  |  |  | 4.00 |  |  |  | 0.38 |
Underlying Share Price ($) |  |  | 4.88 |  |  |  | 19.66 |  |  |  | 11.18 |
Exercise price ($) |  |  | 637 |  |  |  | 637 |  |  |  | 637 |
Warrants fair value ($) |  |  | 0 |  |  |  | 0 |  |  |  | 0.36 |
| c. | Financial risk factors:
The Company’s activities expose it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company’s comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company’s financial performance. Risk management is performed by management in accordance with the policies approved by the Board. The Board establishes written principles for the overall risk management activities as well as specific policies with respect to certain exposures to risks such as exchange rate risk, credit risk and the investments of surplus funds.
| 1. | Market risks:
Foreign currency risk: The Company is exposed to exchange rate risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized liabilities that are denominated in a foreign currency other than the functional currency.
| 2. | Credit risks:
All cash and restricted deposits related to the Company are held in two banks in Israel which are considered financially solid.
| 3. | Liquidity risk:
The Company monitors the risk of a shortage of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2023, the Company expects to settle all of its financial liabilities in less than one year. The carrying amounts of cash and restricted deposits, and all other financial assets and liabilities approximate their fair value. Refer to Note 14a for more information.

X
- Definition The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2023-01-01 -Paragraph 31 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2023-01-01 -Paragraph 7 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard -URIDate 2023-03-23 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2023-01-01 -Paragraph 35K -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | sprcy_FinancialInstrumentsAbstract
Namespace Prefix: | sprcy_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration